Global C-MET & HGF Inhibitors Market Size, Share, Trends and Forecast 2022-2030

Description

c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF).
Industry Insights

Due to the COVID-19 pandemic, the global C-MET & HGF Inhibitors market size is estimated to be worth US$ 2294.7 million in 2021 and is forecast to a readjusted size of US$ 10450 million by 2028 with a CAGR of 23.9% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe C-MET & HGF Inhibitors market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe C-MET & HGF Inhibitors landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

There are three kinds of C-MET / HGF Inhibitors, which are Cabozantinib, Crizotinib and Others. Cabozantinib hold the largest share of the C-MET / HGF Inhibitors market, with a revenue market share nearly 66% in 2019.

C-MET / HGF Inhibitors is sold through Hospitals and Drugs Store. The most proportion of C-MET / HGF Inhibitors is sold through Hospitals, and the market share in 2019 is about 77%.

North America is the largest consumption place, with a consumption market share nearly 60% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of about 34%.

Shandong Exelixis, Ipsen, Pfizer, etc. are the leader of the industry, and top 3 players hold about 100% revenue market share.

This report focuses on C-MET & HGF Inhibitors volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall C-MET & HGF Inhibitors market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Post-covid-19 Outlook

The readers in the section will understand how the C-MET & HGF Inhibitors market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Segmental Outlook

Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).

Segment by Type

Cabozantinib

Crizotinib

Others

Segment by Application

Hospital

Drug Store

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Competitive Scenario

In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Exelixis

Ipsen

Pfizer

Novartis

Takeda

Merck KGaA

Merck

Daiichi Sankyo

GSK

Bristol-Myers Squibb(BMS)

Roche

AVEO Pharmaceuticals

Amgen

AstraZeneca

Mirati Therapeutics

Eli Lilly

Johnson & Johnson

Eisai

Hutchison MediPharma

Kringle Pharmaceuticals

TABLE OF CONTENT

1 C-MET & HGF Inhibitors Market Overview
1.1 Product Overview and Scope of C-MET & HGF Inhibitors

1.2 C-MET & HGF Inhibitors Segment by Type

1.2.1 Global C-MET & HGF Inhibitors Sales Growth Rate Comparison by Type (2022-2028)

1.2.2 Cabozantinib

1.2.3 Crizotinib

1.2.4 Others

1.3 C-MET & HGF Inhibitors Segment by Application

1.3.1 Global C-MET & HGF Inhibitors Sales Comparison by Application: (2022-2028)

1.3.2 Hospital

1.3.3 Drug Store

1.4 Global C-MET & HGF Inhibitors Market Size Estimates and Forecasts

1.4.1 Global C-MET & HGF Inhibitors Revenue 2017-2028

1.4.2 Global C-MET & HGF Inhibitors Sales 2017-2028

1.4.3 C-MET & HGF Inhibitors Market Size by Region: 2017 Versus 2021 Versus 2028

2 C-MET & HGF Inhibitors Market Competition by Manufacturers

2.1 Global C-MET & HGF Inhibitors Sales Market Share by Manufacturers (2017-2022)

2.2 Global C-MET & HGF Inhibitors Revenue Market Share by Manufacturers (2017-2022)

2.3 Global C-MET & HGF Inhibitors Average Price by Manufacturers (2017-2022)

2.4 Manufacturers C-MET & HGF Inhibitors Manufacturing Sites, Area Served, Product Type

2.5 C-MET & HGF Inhibitors Market Competitive Situation and Trends

2.5.1 C-MET & HGF Inhibitors Market Concentration Rate

2.5.2 The Global Top 5 and Top 10 Largest C-MET & HGF Inhibitors Players Market Share by Revenue

2.5.3 Global C-MET & HGF Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 C-MET & HGF Inhibitors Retrospective Market Scenario by Region

3.1 Global C-MET & HGF Inhibitors Retrospective Market Scenario in Sales by Region: 2017-2022

3.2 Global C-MET & HGF Inhibitors Retrospective Market Scenario in Revenue by Region: 2017-2022

3.3 North America C-MET & HGF Inhibitors Market Facts & Figures by Country

3.3.1 North America C-MET & HGF Inhibitors Sales by Country

3.3.2 North America C-MET & HGF Inhibitors Revenue by Country

3.3.3 U.S.

3.3.4 Canada

3.4 Europe C-MET & HGF Inhibitors Market Facts & Figures by Country

3.4.1 Europe C-MET & HGF Inhibitors Sales by Country

3.4.2 Europe C-MET & HGF Inhibitors Revenue by Country

3.4.3 Germany

3.4.4 France

3.4.5 U.K.

3.4.6 Italy

3.4.7 Russia

3.5 Asia Pacific C-MET & HGF Inhibitors Market Facts & Figures by Region

3.5.1 Asia Pacific C-MET & HGF Inhibitors Sales by Region

3.5.2 Asia Pacific C-MET & HGF Inhibitors Revenue by Region

3.5.3 China

3.5.4 Japan

3.5.5 South Korea

3.5.6 India

3.5.7 Australia

3.5.8 Taiwan

3.5.9 Indonesia

3.5.10 Thailand

3.5.11 Malaysia

3.5.12 Philippines

3.5.13 Vietnam

3.6 Latin America C-MET & HGF Inhibitors Market Facts & Figures by Country

3.6.1 Latin America C-MET & HGF Inhibitors Sales by Country

3.6.2 Latin America C-MET & HGF Inhibitors Revenue by Country

3.6.3 Mexico

3.6.4 Brazil

3.6.5 Argentina

3.7 Middle East and Africa C-MET & HGF Inhibitors Market Facts & Figures by Country

3.7.1 Middle East and Africa C-MET & HGF Inhibitors Sales by Country

3.7.2 Middle East and Africa C-MET & HGF Inhibitors Revenue by Country

3.7.3 Turkey

3.7.4 Saudi Arabia

3.7.5 UAE

4 Global C-MET & HGF Inhibitors Historic Market Analysis by Type

4.1 Global C-MET & HGF Inhibitors Sales Market Share by Type (2017-2022)

4.2 Global C-MET & HGF Inhibitors Revenue Market Share by Type (2017-2022)

4.3 Global C-MET & HGF Inhibitors Price by Type (2017-2022)

5 Global C-MET & HGF Inhibitors Historic Market Analysis by Application

5.1 Global C-MET & HGF Inhibitors Sales Market Share by Application (2017-2022)

5.2 Global C-MET & HGF Inhibitors Revenue Market Share by Application (2017-2022)

5.3 Global C-MET & HGF Inhibitors Price by Application (2017-2022)

6 Key Companies Profiled

6.1 Exelixis

6.1.1 Exelixis Corporation Information

6.1.2 Exelixis Description and Business Overview

6.1.3 Exelixis C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.1.4 Exelixis C-MET & HGF Inhibitors Product Portfolio

6.1.5 Exelixis Recent Developments/Updates

6.2 Ipsen

6.2.1 Ipsen Corporation Information

6.2.2 Ipsen Description and Business Overview

6.2.3 Ipsen C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.2.4 Ipsen C-MET & HGF Inhibitors Product Portfolio

6.2.5 Ipsen Recent Developments/Updates

6.3 Pfizer

6.3.1 Pfizer Corporation Information

6.3.2 Pfizer Description and Business Overview

6.3.3 Pfizer C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.3.4 Pfizer C-MET & HGF Inhibitors Product Portfolio

6.3.5 Pfizer Recent Developments/Updates

6.4 Novartis

6.4.1 Novartis Corporation Information

6.4.2 Novartis Description and Business Overview

6.4.3 Novartis C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Novartis C-MET & HGF Inhibitors Product Portfolio

6.4.5 Novartis Recent Developments/Updates

6.5 Takeda

6.5.1 Takeda Corporation Information

6.5.2 Takeda Description and Business Overview

6.5.3 Takeda C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.5.4 Takeda C-MET & HGF Inhibitors Product Portfolio

6.5.5 Takeda Recent Developments/Updates

6.6 Merck KGaA

6.6.1 Merck KGaA Corporation Information

6.6.2 Merck KGaA Description and Business Overview

6.6.3 Merck KGaA C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.6.4 Merck KGaA C-MET & HGF Inhibitors Product Portfolio

6.6.5 Merck KGaA Recent Developments/Updates

6.7 Merck

6.6.1 Merck Corporation Information

6.6.2 Merck Description and Business Overview

6.6.3 Merck C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Merck C-MET & HGF Inhibitors Product Portfolio

6.7.5 Merck Recent Developments/Updates

6.8 Daiichi Sankyo

6.8.1 Daiichi Sankyo Corporation Information

6.8.2 Daiichi Sankyo Description and Business Overview

6.8.3 Daiichi Sankyo C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.8.4 Daiichi Sankyo C-MET & HGF Inhibitors Product Portfolio

6.8.5 Daiichi Sankyo Recent Developments/Updates

6.9 GSK

6.9.1 GSK Corporation Information

6.9.2 GSK Description and Business Overview

6.9.3 GSK C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.9.4 GSK C-MET & HGF Inhibitors Product Portfolio

6.9.5 GSK Recent Developments/Updates

6.10 Bristol-Myers Squibb(BMS)

6.10.1 Bristol-Myers Squibb(BMS) Corporation Information

6.10.2 Bristol-Myers Squibb(BMS) Description and Business Overview

6.10.3 Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.10.4 Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Product Portfolio

6.10.5 Bristol-Myers Squibb(BMS) Recent Developments/Updates

6.11 Roche

6.11.1 Roche Corporation Information

6.11.2 Roche C-MET & HGF Inhibitors Description and Business Overview

6.11.3 Roche C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.11.4 Roche C-MET & HGF Inhibitors Product Portfolio

6.11.5 Roche Recent Developments/Updates

6.12 AVEO Pharmaceuticals

6.12.1 AVEO Pharmaceuticals Corporation Information

6.12.2 AVEO Pharmaceuticals C-MET & HGF Inhibitors Description and Business Overview

6.12.3 AVEO Pharmaceuticals C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.12.4 AVEO Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio

6.12.5 AVEO Pharmaceuticals Recent Developments/Updates

6.13 Amgen

6.13.1 Amgen Corporation Information

6.13.2 Amgen C-MET & HGF Inhibitors Description and Business Overview

6.13.3 Amgen C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.13.4 Amgen C-MET & HGF Inhibitors Product Portfolio

6.13.5 Amgen Recent Developments/Updates

6.14 AstraZeneca

6.14.1 AstraZeneca Corporation Information

6.14.2 AstraZeneca C-MET & HGF Inhibitors Description and Business Overview

6.14.3 AstraZeneca C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.14.4 AstraZeneca C-MET & HGF Inhibitors Product Portfolio

6.14.5 AstraZeneca Recent Developments/Updates

6.15 Mirati Therapeutics

6.15.1 Mirati Therapeutics Corporation Information

6.15.2 Mirati Therapeutics C-MET & HGF Inhibitors Description and Business Overview

6.15.3 Mirati Therapeutics C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.15.4 Mirati Therapeutics C-MET & HGF Inhibitors Product Portfolio

6.15.5 Mirati Therapeutics Recent Developments/Updates

6.16 Eli Lilly

6.16.1 Eli Lilly Corporation Information

6.16.2 Eli Lilly C-MET & HGF Inhibitors Description and Business Overview

6.16.3 Eli Lilly C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.16.4 Eli Lilly C-MET & HGF Inhibitors Product Portfolio

6.16.5 Eli Lilly Recent Developments/Updates

6.17 Johnson & Johnson

6.17.1 Johnson & Johnson Corporation Information

6.17.2 Johnson & Johnson C-MET & HGF Inhibitors Description and Business Overview

6.17.3 Johnson & Johnson C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.17.4 Johnson & Johnson C-MET & HGF Inhibitors Product Portfolio

6.17.5 Johnson & Johnson Recent Developments/Updates

6.18 Eisai

6.18.1 Eisai Corporation Information

6.18.2 Eisai C-MET & HGF Inhibitors Description and Business Overview

6.18.3 Eisai C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.18.4 Eisai C-MET & HGF Inhibitors Product Portfolio

6.18.5 Eisai Recent Developments/Updates

6.19 Hutchison MediPharma

6.19.1 Hutchison MediPharma Corporation Information

6.19.2 Hutchison MediPharma C-MET & HGF Inhibitors Description and Business Overview

6.19.3 Hutchison MediPharma C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.19.4 Hutchison MediPharma C-MET & HGF Inhibitors Product Portfolio

6.19.5 Hutchison MediPharma Recent Developments/Updates

6.20 Kringle Pharmaceuticals

6.20.1 Kringle Pharmaceuticals Corporation Information

6.20.2 Kringle Pharmaceuticals C-MET & HGF Inhibitors Description and Business Overview

6.20.3 Kringle Pharmaceuticals C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.20.4 Kringle Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio

6.20.5 Kringle Pharmaceuticals Recent Developments/Updates

7 C-MET & HGF Inhibitors Manufacturing Cost Analysis

7.1 C-MET & HGF Inhibitors Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Key Suppliers of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.3 Manufacturing Process Analysis of C-MET & HGF Inhibitors

7.4 C-MET & HGF Inhibitors Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

8.1 Marketing Channel

8.2 C-MET & HGF Inhibitors Distributors List

8.3 C-MET & HGF Inhibitors Customers

9 C-MET & HGF Inhibitors Market Dynamics

9.1 C-MET & HGF Inhibitors Industry Trends

9.2 C-MET & HGF Inhibitors Market Drivers

9.3 C-MET & HGF Inhibitors Market Challenges

9.4 C-MET & HGF Inhibitors Market Restraints

10 Global Market Forecast

10.1 C-MET & HGF Inhibitors Market Estimates and Projections by Type

10.1.1 Global Forecasted Sales of C-MET & HGF Inhibitors by Type (2023-2028)

10.1.2 Global Forecasted Revenue of C-MET & HGF Inhibitors by Type (2023-2028)

10.2 C-MET & HGF Inhibitors Market Estimates and Projections by Application

10.2.1 Global Forecasted Sales of C-MET & HGF Inhibitors by Application (2023-2028)

10.2.2 Global Forecasted Revenue of C-MET & HGF Inhibitors by Application (2023-2028)

10.3 C-MET & HGF Inhibitors Market Estimates and Projections by Region

10.3.1 Global Forecasted Sales of C-MET & HGF Inhibitors by Region (2023-2028)

10.3.2 Global Forecasted Revenue of C-MET & HGF Inhibitors by Region (2023-2028)

11 Research Finding and Conclusion

12 Methodology and Data Source

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Author List

12.4 Disclaimer

Choose License Type

Checkout Inquiry Sample